Theravance Biopharma
TBPH
107 hedge funds and large institutions have $1.09B invested in Theravance Biopharma in 2021 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 41 reducing their positions, and 13 closing their positions.
29% more call options, than puts
Call options by funds: $2.72M | Put options by funds: $2.11M
15% more capital invested
Capital invested by funds: $946M → $1.09B (+$147M)
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
0% more funds holding
Funds holding: 107 → 107 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.12% less ownership
Funds ownership: 83.21% → 82.09% (-1.1%)
27% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$38M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.58M |
| 3 |
BlackRock
New York
|
+$2.72M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$2.11M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$14.7M |
| 2 |
Morgan Stanley
New York
|
-$8.19M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.77M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$6.27M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$2.81M |
TBPH Hedge Fund Activity: Q1 2021 in Review
107 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q1 2021, worth a combined $1.09B — up 15% from $946M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new TBPH positions and 13 closed out — a net gain of 1 holder — while 30 added to existing stakes and 41 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $38M. The largest seller was Great Point Partners, exiting entirely with an estimated $14.7M sold.
- 107 institutional investors held Theravance Biopharma (TBPH) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $1.09B of Theravance Biopharma stock for Q1 2021, up 15% quarter-over-quarter.
- 14 funds opened new Theravance Biopharma positions in Q1 2021 and 13 closed out, a net change of +1 holder.
- The largest Theravance Biopharma buyer in Q1 2021 was Wellington Management Group, an estimated $38M added.
- The largest Theravance Biopharma seller in Q1 2021 was Great Point Partners, an estimated $14.7M sold.
Based on aggregated 13F filings for Q1 2021.